Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 11/20 | 0.68 |
| ▸ | F13A1 | P00488 | 2/20 | 0.63 |
| ▸ | TGM1 | P22735 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyl Radical SCHEMBL28150321 | 0.98 | TGM2 (0.66) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL21657888 | 0.90 | TGM2 (0.56) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL439369 | 0.87 | TGM2 (0.79) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL24510652 | 0.84 | ALDH1A1 (0.52) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL17327878 | 0.84 | TGM2 (0.63) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL29684447 | 0.83 | TGM2 (0.72) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL39036 | 0.83 | TGM2 (0.72) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL3633294 | 0.83 | TGM2 (0.51) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL6357758 | 0.82 | TGM2 (0.61) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL7470743 | 0.82 | TGM2 (0.67) | TGM2F13A1TGM1LMNATGM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 459 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115708891-B | Developing drug-carrying microsphere based on microfluidic technology and preparation method and application thereof | 四川大学 | 2024-06-18 | — | — | CN | claimed |
| CN-118184818-A | Functionalized high molecular polymer, visualized embolism microsphere prepared by microfluidic technology and application | 四川大学 | 2024-06-14 | — | — | CN | claimed |
| CN-104854123-B | Copolymers for protein precipitation | 默克专利股份公司 | 2020-04-21 | — | — | CN | claimed |
| EP-2935309-B1 | COPOLYMERS FOR PROTEIN PRECIPITATION | MERCK PATENT GMBH (DE) | 2019-01-23 | — | — | EP | claimed |
| US-9926341-B2 | Copolymers for protein precipitation | MERCK PATENT GMBH (DE) | 2018-03-27 | — | — | US | claimed |
| US-5871894-A | CONTAINING CYAN DYE-FORMING COUPLER AND ADDITION COPOLYMER | FUJI PHOTO FILM CO., LTD. (JP) | 1999-02-16 | — | — | US | claimed |
| EP-0881535-A1 | Silver halide color photographic light-sensitive material | Fuji Photo Film Co., Ltd. (JP) | 1998-12-02 | — | — | EP | claimed |
| US-4699867-A | Radiation-sensitive positive working composition and material with aqueous-alkaline soluble acryamide or methacryamide copolymer having hydroxyl or carboxyl groups | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-10-13 | — | — | US | claimed |
| CN-116496219-B | Six-membered and five-membered heterocyclic compound, and pharmaceutical composition and application thereof | 东南大学 | 2026-05-15 | — | — | CN | disclosed |
| US-RE50776-E1 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| WO-2025127092-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | 日産化学株式会社 | 2025-06-19 | — | — | WO | disclosed |
| EP-4568954-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE (CDK) 12 AND/OR CDK13 AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2025-06-18 | — | — | EP | disclosed |
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2025-06-17 | — | — | US | disclosed |
| WO-2025076470-A1 | SOX10 INHIBITORS AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2025-04-10 | — | — | WO | disclosed |
| US-4940711-A | Antihypertensive N-piperazinylalkanoylanilides | RECORDATI, S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1990-07-10 | — | — | US | disclosed |
| US-4749647-A | Polymerization-induced separation assay using recognition pairs | GENETIC SYSTEMS CORPORATION (US) | 1988-06-07 | — | — | US | disclosed |
| US-4699867-A | Radiation-sensitive positive working composition and material with aqueous-alkaline soluble acryamide or methacryamide copolymer having hydroxyl or carboxyl groups | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-10-13 | — | — | US | disclosed |
| EP-0120558-A1 | Antihypertensive N-piperazinylalkanoylanilides | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1984-10-03 | — | — | EP | disclosed |
| US-4210582-A | FIBER-REACTIVE YELLOW DYES FOR WOOL | CIBA-GEIGY CORPORATION (US) | 1980-07-01 | — | — | US | disclosed |
| US-4130702-A | Polyacryloylaminobenzoic acid, polymethacryloylaminobenzoic acid and method of preparation | CELANESE CORPORATION (US) | 1978-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | CDK19, CDK9, CDK1 | TGM2 3352/4885F13A1 2592/4885TGM1 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.